Foresee Pharmaceuticals Co., Ltd.
6576.TWO
Taipei Exchange83.10
TWD
-1.00
- -
Foresee Pharmaceuticals Co., Ltd.
6576.TWO
(Taipei Exchange)
Recent
price
83.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Foresee Pharmaceuticals Co., Ltd. (TPEx: 6576) develops and commercializes biopharmaceutical products focused on stabilized injectable formulation (SIF) long-acting injectable technologies and novel chemical entity (NCE) programs targeting specialty markets, rare diseases, oncology, respiratory disorders, neurology, and high unmet medical needs; its core SIF pipeline includes CAMCEVI (leuprolide mesylate, FP-001) 42 mg and 21 mg approved in the US, Canada, and EU for advanced prostate cancer and launched in the US, with ongoing Phase 3 trials for central precocious puberty and premenopausal breast cancer, FP-014 (triptorelin) in Phase 3 for prostate cancer, FP-016 and FP-017 (undisclosed) for neurology/psychiatry; its NCE portfolio features Aderamastat (FP-025, MMP-12 inhibitor) with Phase 2 proof-of-concept in allergic asthma completed positively and planned for cardiac sarcoidosis, Linvemastat (FP-020, MMP-12 inhibitor) in Phase 2 for asthma/COPD and inflammatory bowel disease, Mirivadelgat (FP-045, ALDH2 activator) in Phase 2 for pulmonary hypertension associated with interstitial lung disease, alongside earlier-stage MMP-12 inhibitors for idiopathic pulmonary fibrosis and neurology, and ALDH2 activators for cardiovascular, renal, metabolic diseases, and neurology. Founded in 2013 and headquartered in Taipei, Taiwan, with US operations, the company conducts R&D and clinical activities in the United States, China, and Europe, serving endocrinology, oncology, respiratory, and rare disease patient populations through proprietary SIF-ADAGIO, SIF-LEGATO, SIF-DUO, and SIF-MEZZO platforms. Recent developments include the completion of a US$42.1 million public financing in December 2024 to advance FP-014 Phase 3 trials, FP-020 Phase 2 studies in asthma and IBD, and FP-045 Phase 2 in PH-ILD; progression of CAMCEVI expansions and NCE programs such as FP-025 positive Phase 2 outcomes; and strategic partnerships including GeneScience Pharmaceuticals for CAMCEVI in China.